Examining CA 19-9 Tumor Marker in Ovarian Dermoid Cysts; A Retrospective Study

Aims Tumor markers are very applicable for examining differential diagnoses of adenosine masses. Increases in CA 19-9 have been reported in epithelial ovarian and endometrial tumors. Dermoid cysts are the most prevalent ovarian germ cell tumors. The aim of the present study was to examine Cancer Antigen 19-9 (CA 19-9) tumor marker in ovarian dermoid cysts. Information and Methods This descriptive-analytic study was conducted using hospital records. By referring to archives of a Imam Khomeini Hospital, Ahwaz, Iran in 2016, the information of 73 patients with ovarian dermoid cysts were extracted that include their demographic information, cyst size, the location of involvement, the presence of symptoms of malignancy in sonography reports, and CA 19-9 serum levels prior to surgery. A pathologic report was used for the final mass diagnosis and determining the type of mass extracted from the patients’ bodies. Data were analyzed by SPSS 22 software using independent-sample t-test, chi-square test and Pearson correlation coefficient. Findings All patients under study were diagnosed with dermoid cysts. In 9 patients (12.85%), symptoms of malignancy were reported in their sonography reports. The mean serum levels of CA 19-9 tumor marker was 46.13±11.65U/ml. There was a direct correlation between mass size and CA 19-9 serum concentrations (r=0.24). In 20% of the patients, the concentrations of CA 19-9 were normal. Conclusion The CA 19-9 serum concentration is related to tumor size in cases of mature cystic teratoma. In most cases of unilateral mature cystic teratomas, the right ovary is mainly preferred to involve. 

Keywords:

Ovarian Neoplasms , Biomarkers Tumor , CA 19-9 , Dermoid Cyst